PeptideDB

Fluoroethylnormemantine hydrochloride

CAS No.: 1639210-25-5

Fluoroethylnormemantine hydrochloride, a Memantine derivative, functions as an antagonist for the N-methyl-D-aspartate (
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description Fluoroethylnormemantine hydrochloride, a Memantine derivative, functions as an antagonist for the N-methyl-D-aspartate (NMDA) receptor. It can also serve as a positron emission tomography (PET) tracer, specifically as [18F]-Fluoroethylnormemantine hydrochloride. Notably, this compound displays a range of effects, including anti-amnesic, neuroprotective, antidepressant-like, and fear-attenuating properties.
In vivo Fluoroethylnormemantine (0.1-10 mg/kg; a single i.p.) shows anti-amnesic effects on Aβ 25-35 -induced learning impairments in mice[1]. Fluoroethylnormemantine (0.1-10 mg/kg; i.p. once daily for 7 days) attenuates Aβ 25-35 -induced behavioral deficits, neuroinflammation, oxidative stress, apoptosis, and cell loss in mice[1]. Fluoroethylnormemantine (1-20 mg/kg; a single injection) decreases behavioral despair in the forced swim test (FST) and reduces fear behavior in the cued fear conditioning (FC) and extinction training in rats[2]. Animal Model: Male Swiss CD-1 mice (7-9 weeks) were injected with Aβ 25-35[1]Dosage: 0.1, 0.3, 1, 3, 10 mg/kg Administration: I.p. 30 minutes before the behavioral tests Result: Attenuated Aβ 25-35 -induced spontaneous alternation deficit, passive avoidance deficit, and novel object exploration deficit.
molecular weight 233.76
Molecular formula C12H21ClFN
CAS 1639210-25-5
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
References 1. Couly S, et, al. Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease. Int J Neuropsychopharmacol. 2021 Feb 15;24(2):142-157. 2. Chen BK, et, al. Fluoroethylnormemantine, a novel derivative of memantine, facilitates extinction learning without sensorimotor deficits. Int J Neuropsychopharmacol. 2021 Feb 25;pyab007. 3. Chen BK, et, al. Fluoroethylnormemantine, a novel NMDA receptor antagonist, for the prevention and treatment of stress-induced maladaptive behavior. Biological Psychiatry. 2021 May 9.